The Umbilical Cord Blood Collection Program (UCBCP), administered by UC Davis Health System, is a new statewide public program designed to capture the genetic diversity of Californians through collection of cord blood units (CBUs) for unrelated transplantation. This program is funded with revenue from California state birth certificate fees. The vision for the implementation of the mission by UCBCP is to expand access to cord blood stem cells by targeting current inventory deficiencies to provide greater probabilities that people of any race or ethnicity will find an appropriately matched CBU in the National Cord Blood Inventory (NCBI). In support of these goals, the UCBCP plans to promote targeted education programs for health professionals and to utilize best practices for cord blood collections. Through this process UCBCP will facilitate the provision of high quality CBUs for transplantation, as well as promote research and development of effective treatments utilizing cord blood stem cells by making the CBUs collected that do not meet the criteria for banking available to researchers. Much progress has been made toward developing a sustainable cord blood collection program for the state over the first year. The UCBCP leadership team has been developed and we have identified cord blood banks through an RFP bidding process that will be partnered with hospitals in various parts of the state. The UCBCP is in varying stages of contract negotiations with three of the public banks who responded to the RFP. To date negotiations are in place for California collections in Southern California to occur at five Scripps hospitals, funded in part by the UCBCP; and by collections set to begin at 13 Kaiser Hospitals, also with support from the UCBCP. In the Central Valley, a collection site is being developed in Fresno, at the Community Regional Medical Center. In the Bay area the UCBCP is in negotiations with several hospitals, including California Pacific Medical Center and Alta Bates. In the Sacramento area, the UCBCP has commitments from 2 hospitals and are seeking the same from two additional birthing centers. At UCDHS, we have received IRB approval for the program, and have now initiated cord blood collections for purposes of collector training and process validation.
The Umbilical Cord Blood Collection Program (UCBCP), administered by UC Davis Health System, is a new statewide public program designed to capture the genetic diversity of Californians through collection of cord blood units (CBUs) for unrelated transplantation. This program is funded with revenue from California state birth certificate fees. The vision for the implementation of the mission by UCBCP is to expand access to cord blood stem cells by targeting current inventory deficiencies to provide greater probabilities that people of any race or ethnicity will find an appropriately matched CBU in the National Cord Blood Inventory (NCBI). In support of these goals, the UCBCP plans to promote targeted education programs for health professionals and to utilize best practices for cord blood collections. Through this process UCBCP will facilitate the provision of high quality CBUs for transplantation, as well as promote research and development of effective treatments utilizing cord blood stem cells by making the CBUs collected that do not meet the criteria for banking available to researchers. Much progress has been made toward developing a sustainable cord blood collection program for the state over the first year. The UCBCP leadership team has been developed and we have identified cord blood banks through an RFP bidding process that will be partnered with hospitals in various parts of the state. The UCBCP is in varying stages of contract negotiations with three of the public banks who responded to the RFP. To date negotiations are in place for California collections in Southern California to occur at five Scripps hospitals, funded in part by the UCBCP; and by collections set to begin at 13 Kaiser Hospitals, also with support from the UCBCP. In the Central Valley, a collection site is being developed in Fresno, at the Community Regional Medical Center. In the Bay area the UCBCP is in negotiations with several hospitals, including California Pacific Medical Center and Alta Bates. In the Sacramento area, the UCBCP has commitments from 2 hospitals and are seeking the same from two additional birthing centers. At UCDHS, we have received IRB approval for the program, and have now initiated cord blood collections for purposes of collector training and process validation. The association between HLA-DP and hematopoietic stem cell transplantation (HCT) outcomes is still questionable. In the present study, we examined 80 patients who underwent first allogeneic HCT between the years of 2005-2008 and were followed up for at least 2 years post transplant. These patients were 10/10 matched for HLA-A, -B, -C, -DR and -DQ at high resolution using Sequence Specific Priming (SSP) and/ or Sequence Based Typing (SBT). We analyzed the impact of donor/recipient (D/R) mismatches at HLA-DPA1 and HLA-DPB1 on different HCT outcomes including aGVHD, cGVHD, and risk of disease relapse in a single center study. Additionally, we classified HLA-DPB1 mismatches as permissive or non-permissive according to a previously described TCE4 algorithm and attempted to confirm its efficacy. Each categorical testing variable were compared with the different clinical end points by 2-tailed Fischer's exact test. The magnitude of effect was estimated by risk ratios and their 95% confidence intervals. "p" value 0.05 (two-sided) was considered significant. A total of 160 alleles were observed at HLA-DPA1 and 159 alleles were observed at HLA-DPB1 locus. HLA-DPA1 and DPB1 allelic frequencies in the study population were not significantly different from those previously observed in other Caucasian populations. At DPA1 locus, D/R mismatching was observed in 15% of D/R pairs, however almost all of them were mismatched at the level of single allele. Since only one patient was mismatched for both DPA1 alleles, the effect of DPA1 mismatches were not analyzed for single or double mismatches. At the DPB1 locus, 44% D/R pairs were found mismatched, including 24% for single allele and 20% for both alleles. No variables analyzed (allelic or non-permissive mismatches) were significantly associated with any transplant outcomes evaluated in this patient cohort. Our study did not confirm the association between HLA-DP mismatches and HCT outcomes. The TCE4 algorithm also did not yield significant advantageous results. Our results are in accord with a recent French study but disconcordant with various studies conducted elsewhere, including the United States and the United Kingdom. Further molecular study of HLA-DP in the clinical setting is warranted to further elucidate the role of this gene and its mismatching on HCT outcome. 
